CHICAGO, Dec. 17, 2012 /PRNewswire/ -- ICAP Patent Brokerage announces for sale a patented method for creating an improved topical analgesic cream from MyoRX Corp., which can be used to treat arthritis and other chronic pain syndromes as well as muscle strains, burns, and neuropathic pain.
Topical analgesic creams have been advocated as first line treatments for a wide range of pain disorders. However, the product options currently available to doctors and patients are all water based compounds. Therefore, these compounds cannot penetrate the skin barrier for cellular delivery, thereby reducing the effectiveness of the medication. The portfolio for sale utilizes omega-3 fatty acids in combination with aspirin to create an enhanced, cost-effective medical delivery mechanism with minimal side effects.
"We are excited to offer this innovative topical cream to our global base of buyers. The portfolio provides an inexpensive and safe solution for individuals of all ages – from young athletes to elderly retirees – seeking an improved method for pain relief from a wide range of chronic pain ailments and issues. Accordingly, this package is relevant to consumer pharmaceutical companies and healthcare firms wishing to formulate the next generation in topical multipurpose pain relievers for the public," says Dean Becker, CEO of ICAP Patent Brokerage.
Key Characteristics & Benefits
The assets for sale disclose methods for an enhanced topical analgesic cream that features superior transdermal absorption and absorption speed. The fundamental science underlying the topical solution leverages the lipophilic properties of omega-3 fatty acids in combination with aspirin. It is presumed that the resultant compound is resolvin-1, known to be an extremely potent anti-inflammatory mediator. Further, this topical cream can be manufactured inexpensively and has a wide range of applications beyond pure anti-inflammatory treatment. For example, it can be used for tendonitis, muscle strains, burns, wound healing, cosmetic dermatologic purposes, and for treating neuropathic pain. Further, the patented topical compound has had an extraordinary safety record and historically has been used in the elderly population, teenagers, and athletes across both professional and collegiate sports. Therefore, this portfolio would be of interest to consumer pharmaceutical companies and healthcare practitioners operating in the orthopedic, chiropractic, chronic pain, and sports medicine fields.
The topical analgesic described by the patent portfolio has had numerous direct or related scientific studies performed to provide certainty to its efficacy. Specific empirical evidence to support the portfolio can be reviewed via the technical description of this IP sales offering.
To learn more about the assets available for sale in this portfolio:
Contact Dean Becker of ICAP Patent Brokerage at (561) 309-0011 or via email at Dean.Becker@us.icap.com.
About ICAP Patent Brokerage
ICAP Patent Brokerage is a division of ICAP plc and the world's largest intellectual property brokerage and patent auction firm.
ICAP is the world's leading interdealer broker and provider of post trade risk and information services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, FX, emerging markets and equity derivatives through voice and electronic networks. Through our post trade risk and information services we help our customers manage and mitigate risks in their portfolios. For more information, go to www.icap.com.
SOURCE ICAP Patent Brokerage